Chiesi is offering $27-per-share for Framingham, Massachusetts-based KalVista, valuing the company at around $1.9 billion, ...

Board‑level appointments this month were thick and fast, with six Boards adding new faces as Chairperson, as well as several ...

In a statement, Prime Minister Keir Starmer said the "significant investment" had been "made possible by the pharmaceutical ...

The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur, saying this could ...

Delivering a shared agenda for the UK’, it explored how to ensure NHS patients benefit from the latest medicines and vaccines ...

GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new ...

A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main ...

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept Therapeutics with a decision not to approve relacorilant, a drug for a rare hormonal disorder that ...

UK biotech OMass Therapeutics has revealed its first major pharma partnership, with Roche's Genentech unit paying $20 million upfront to tap into its expertise and find small-molecule therapies for ...

After years of wrangling, OxyContin manufacturer Purdue Pharma is on the brink of a bankruptcy agreement that could allow it ...

California, US AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25 billion, that ...

A court in Munich has granted a preliminary injunction that will prevent MSD from distributing the subcutaneous version of its cancer immunotherapy Keytruda in the German market. The verdict is the ...